{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-004795","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.676798+00:00","generated_at":"2026-05-16T09:33:12.542840+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026","bullets":["Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.","Mean EASI reduction at day 56: 72% for soquelitinib vs 40% for placebo; separation statistically significant (p=0.035).","No new safety signals; AE rates 41.7% soquelitinib vs 50% placebo, all Grade 1-2, no dose modifications.","Activity seen in patients with prior systemic therapy including dupilumab/JAK inhibitors.","Plans to initiate Phase 2 trial in moderate-to-severe atopic dermatitis in Q1 2026 (approx. 200 patients, 4 arms)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-004795","json":"https://secwatch.observer/filing/0001104659-26-004795.json","markdown":"https://secwatch.observer/filing/0001104659-26-004795.md","text":"https://secwatch.observer/filing/0001104659-26-004795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/0001104659-26-004795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/tm263501d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:33:12.542840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}